Koninklijke BAM Groep NV (0LNQ)
London Exchange · UK · prices in EUR · close of 20 Oct 2026
Key indicators
| Last close | EUR 11.71 |
|---|---|
| 52-week range | 7.11 – 13.13 |
| Return, 1 month / 3 months | −2.4% / +2.3% |
| Return, 1 year / 3 years | +63.9% / +611.4% |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 49 |
| Volatility (1 year) | 39.9% |
| Worst drawdown (1 year) | -17.2% |
| Average daily value traded | 0.91M EUR |
| Dividend yield | 2.6% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Koninklijke BAM Groep is a Dutch construction and engineering group based in the Netherlands. It designs and builds infrastructure such as roads, bridges and rail systems, constructs and renovates buildings, and carries out civil engineering and property work. Its customers include governments, public bodies and private clients, and its operating companies work on projects in the Netherlands, the United Kingdom, Belgium, Germany and other markets. The group also provides maintenance and technical services for the structures and buildings it delivers.
Koninklijke BAM Groep NV trades under the code 0LNQ on the London Exchange in UK, with its price quoted in euros (EUR). Our dividend records, which start in 2019, show payments in 5 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Koninklijke BAM Groep NV (0LNQ) trades on the London Exchange in UK. It last closed at EUR 11.71 on 20 October 2026.
Its price-based Market X-Ray is 66 out of 100 (a fair price profile), ranking 809 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 63.9% and over the last three months it rose 2.3%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 78 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 12.9% | ||
| From 52-week high | -9.2% | ||
| Momentum | 80 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 2.3% | ||
| 6-month return | 26.7% | ||
| 12-month return, skipping the last month | 67.8% | ||
| Stability (higher is calmer) | 61 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 39.9% | ||
| Worst drawdown, 1 year (smaller is calmer) | -17.2% | ||
| Liquidity | 51 · Fair | Moderate trading activity. | |
| Average daily value traded | 0.91M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 38 · Weak | Dividend is small or irregular. | |
| Dividend yield | 2.6% | ||
| Years with dividends | 4 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
Weak spots
- Income: Dividend is small or irregular.
Returns
| 1 week | +1.8% |
|---|---|
| 1 month | −2.4% |
| 3 months | +2.3% |
| 6 months | +26.7% |
| 1 year | +63.9% |
| 3 years | +611.4% |
| 5 years | +451.9% |
Signals
| 50-day / 200-day average | 11.73 / 10.37 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.33 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 11 May 2026 | EUR 0.3000 |
| 12 May 2025 | EUR 0.2500 |
| 12 Apr 2024 | EUR 0.2000 |
| 14 Apr 2023 | EUR 0.1500 |
| 23 Apr 2019 | EUR 0.1400 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.